Αποτελέσματα Αναζήτησης
20 Ιουλ 2021 · An optimal MIB-1 index cut-off value (≥6/<6) in the prediction of recurrence was determined by ROC curve analysis (AUC: 0.71; 95% CI: 0.55–0.87). A high MIB-1 index (≥6%) was present in 50 cases (24.0%) and was significantly associated with male sex, peritumoral edema, low baseline CRP, and low fibrinogen level in the multivariate analysis.
16 Νοε 2012 · The median MIB-1 index was 12.9% (range, 0.8%-79.9%). The median observation period for living patients was 59 months. The estimated 5-years progression-free survival (PFS) and 5-years overall survival (OS) rates were 48% and 84%, respectively.
21 Σεπ 2013 · The 5-year overall survival (OS) for an MIB-1 labeling index of ≥10% and <10% was 77% and 92%, respectively (P = 0.025). Pathological grading was not correlated with PFS or OS. In multivariate analysis, an MIB-1 labeling index of ≥10% was independently associated with poor PFS and OS.
We assess the correlation of MIB-1 LI and tumor growth velocity (TGV), aiming to contribute to the understanding of clinical implications and the predictive value of MIB-1 LI as an indicator of proliferative activity and progression-free survival (PFS) in PLGG.
1 Δεκ 2015 · Results: MIB-1 LI was related with disease-free survival and overall survival in both adenocarcinoma (ADC) and squamous cell carcinoma (SQCC). In ADC, high MIB-1 LI (optimized validated cut off: 10.6%) was an independent negative prognosticator (Hazards ratio: 2.53, 95% Confidential interval: 1.69-3.77, p < 0.01).
20 Ιουλ 2021 · We found four easily identifiable and routinely recorded risk factors for an increased MIB-1 index and developed a simple and quick-to-use score that allows us to estimate the risk of an elevated MIB-1 index prior to the surgical resection. Furthermore, this score seems to predict the progression-free survival in intracranial meningiomas.
16 Νοε 2001 · MIB-1 expression was correlated with baseline clinicopath-ologic parameters, as well as recurrence (RR), disease-free (DFS), and overall survival (OS) rates. Median follow-up among survivors was 6.5 years (range, 5.6–. 17.5). RESULTS.
